Eurofins CDMO Alphora Expands Capacity and HPAPI Capabilities
Eurofins CDMO Alphora has expanded its kilolab and high-potency active pharmaceutical ingredient (HPAPI) development and manufacturing capabilities in Ontario.
The expanded laboratory capacity supports growing demand for flexibility in process development, scale-up, and manufacturing for both non-high-potency and high-potency programs. The new suites total 627 sq ft and are equipped with walk-in fume hoods capable of supporting up to 100L glass reactors. The flexible design accommodates specialized equipment, including isolators, glove boxes, and lyophilizers, that can be brought in as needed depending on project requirements.
Eurofins laboratories are supported by a dedicated analytical laboratory and an adjacent GMP warehouse, creating an integrated setup spanning development, analytical support, material management, and manufacturing readiness.
The expansion adds capacity for handling increasingly complex and highly potent molecules across development stages. It also extends the site's integrated antibody-drug conjugate (ADC) capabilities, enabling production of linkers and payloads for conjugation with monoclonal antibodies manufactured on-site, reducing the need to coordinate across multiple external suppliers.
The move reflects broader industry demand for capacity to support targeted therapies and next-generation medicines.
